ArticleGynecologic oncology reports2026
Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objectives: To evaluate temporal trends in estrogen replacement therapy (ERT) utilization among younger gynecologic cancer survivors. Methods: We conducted a cross-sectional study using the Merative MarketScan Research Database from January 1, 2013, through December 31, 2021. We included female patients aged 18-51 years with a diagnosis or history of gynecologic cancer. Annual prevalence of ERT use was calculated, and trends over time were assessed using annual percent change (APC) and 95% confidence intervals (CIs). Results were assessed across cancer types and age groups. Results: ERT utilization increased from 10.9% in 2013 to 14.1% in 2021 among all gynecologic cancer survivors (APC 3.41%, 95% CI 2.13-4.71%). Increasing ERT use was observed across all gynecologic cancer subgroups and age categories during the study period. Ovarian cancer survivors consistently had the greatest prevalence of ERT use, whereas uterine cancer survivors had the lowest prevalence across the study period. Among the age sub-groups, the 18-34 years old age group had the largest increase in ERT utilization, from 6.8% to 10.5% (APC 5.68%, 95% CI 3.1-8.33) over the study period. Conclusions: ERT utilization among younger gynecologic cancer survivors increased between 2013 and 2021. As ERT use continues to rise in this population, further research is needed to identify patient-, provider-, and system-level factors associated with prescribing and uptake and to evaluate gaps in menopausal survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.